Back to today’s briefing

Story perspectives

Celcuity's Gedatolisib Shows 76% Breast Cancer Progression Reduction

7/28/2025

24 2

Summary

Story summary

Celcuity Inc., hailing from Minneapolis, is making strides in the fight against cancer with its promising drug, gedatolisib. Demonstrating a remarkable 76% reduction in disease progression for advanced breast cancer, the company is set to submit a New Drug Application to the FDA by late 2025, potentially revolutionizing oncology treatment.

1 of 1

Story summary

Celcuity Inc., hailing from Minneapolis, is making strides in the fight against cancer with its promising drug, gedatolisib. Demonstrating a remarkable 76% reduction in disease progression for advanced breast cancer, the company is set to submit a New Drug Application to the FDA by late 2025, potentially revolutionizing oncology treatment.